The landscape of cancer diagnostics is evolving with molecular and protein biomarkers indispensable for accurate diagnosis, therapy selection, monitoring treatment response, and early detection of cancer recurrence. Kalorama Information’s The World Market for Cancer Diagnostics, 2024-2029 delivers an authoritative and comprehensive analysis of the global cancer in vitro diagnostics (IVD) market, including industry-defining trends, market sizing, and growth opportunities.

This report offers an in-depth review of the cancer IVD market, including expert insights into significant segment markets:

• Oncology molecular assays (including companion diagnostics)
• Molecular screening for colorectal cancer
• Immunohistochemistry (IHC)
• Tumor marker immunoassays
• In situ hybridization (ISH/FISH)
• Human papillomavirus (HPV) tests
• Circulating tumor cell (CTC) assays

While focusing on these pivotal categories, the report provides limited coverage of imaging, hematology, clinical chemistry, flow cytometry, Pap smears, and traditional stains. Key developments, product launches, and regulatory announcements that shape the cancer IVD market are analyzed, along with forecasts for market growth from 2024 to 2029.

Key Highlights

• Shift to Biofluid-Based Diagnostics: Although tissue-based diagnostics dominate the current market, there is growing momentum toward biofluid-based tests (e.g., blood, urine) for cancer detection and monitoring.
• Market Dynamics: The forecasted growth reflects anticipated product innovations, cancer epidemiology trends, and demographic shifts, with revenue estimates based on factory-level sales to end users.
• Comprehensive Insights: The report incorporates global cancer statistics, technological advancements, and competitive trends to provide a nuanced view of the market’s evolution.

Report Structure

1. Executive Summary – A concise overview of key findings and market scope.
2. Introduction and Overview – Background and terminology for context.
3. Market Trends – Emerging trends shaping the cancer diagnostics industry.
4. Market Revenues and Forecasts – Detailed revenue projections by segment through 2029.
5. Competitive Analysis – Analysis of key market players and competitive developments.
6. Corporate Profiles – Profiles of leading companies in the cancer diagnostics space.

Methodology

The report leverages a robust combination of primary and secondary research. Sources include company reports, government documents, research journals, and industry databases. In-depth interviews with key stakeholders, such as company representatives, researchers, and clinicians, further validate the market forecasts and uncover emerging opportunities.

Major data sources include the American Cancer Society, FDA, World Health Organization, Cancer Research UK, and the European Diagnostic Manufacturers Association, among others. Kalorama Information’s proprietary databases and previous market reports also provide foundational insights.